HC Wainwright & Co. Reiterates Buy on Cytokinetics, Maintains $49 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Joseph Pantginis reiterates a Buy rating on Cytokinetics (NASDAQ:CYTK) and maintains a $49 price target.
May 22, 2023 | 10:08 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cytokinetics (NASDAQ:CYTK) receives a reiterated Buy rating from HC Wainwright & Co. analyst Joseph Pantginis, with a maintained $49 price target.
The reiterated Buy rating and maintained $49 price target by HC Wainwright & Co. analyst Joseph Pantginis indicates a positive outlook for Cytokinetics in the short term. This news is likely to boost investor confidence and potentially drive the stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100